$EXEL

Nuvera, an Inizio Engage brand, announced winners of its 2026 Best-in-Class Patient Support Program Awards, with AbbVie, Sanofi/Regeneron, Pfizer, and Genentech among the top large pharma companies across various therapeutic areas. Rankings are based on feedback from over 2,300 physicians and healthcare staff. Winners will be recognized at the Informa Patient Pathways Congress in November. Nuvera also noted the increasing role of AI in patient support programs.

TD Cowen kept Exelixis at Buy and raised its price target to $76 from $55, implying a 14.8% upside from the Oct 29 close of $66.20. Recent analyst targets range from $54 to $65.

RBC Capital kept Exelixis at Sector Perform, raising its price target to $58 from $51. This implies a 12.4% downside from the Oct 29 close of $66.20. Recent analyst targets range from $51 to $65.

Truist Securities kept its Hold rating on Exelixis but increased its price target to $60 from $54, suggesting a 9.4% downside from the last close. Recent analyst price targets for the company range from $51 to $65.

Barclays kept Exelixis at Equal-Weight, raising its price target to $54 from $49, implying an 18.4% downside from the recent close. Recent analyst targets range from $51 to $65.

Exelixis, Inc.'s average stock price target increased to $58.29, up from $55.5, based on estimates from 14 analysts, with a range of $41 to $76. This implies a 12% downside from the Oct. 29 closing price. The consensus rating remains 'Buy' among 19 analysts.

EXELIXIS, INC. (EXEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Andrew Peters SVP, Strategy & Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces Third Quarter 2026 Financial Results and Provides Corp

Exelixis reported Q3 2026 revenues of $605M, driven by its cabozantinib franchise. The company also highlighted progress in its zanzalintinib development program, with ongoing trials and expected topline results in Q1 2027. Exelixis updated its 2026 financial guidance, reflecting these developments.

Exelixis (EXEL) shares rose 49% this year, but the FDA extended its review of zanzalintinib, a colorectal cancer drug, to 2027. Despite this, the company highlights three growth drivers: Cabometyx's patent protection until 2030, zanzalintinib's potential $4.5B sales by 2033, and a deep pipeline of oncology drugs. Q2 revenue increased 10.6% to $628.7M, with EPS up 26% to $0.82.

Citizens raised Exelixis (EXEL) price target to $65, citing strong data on cabozantinib. EXEL trades near 52-week high, up 58.5% YTD. Q2 earnings beat EPS estimates but missed on revenue. FDA extended zanzalintinib review. Citizens maintains Outperform, BMO initiates with Perform rating.